DK1256339T3 - Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom - Google Patents
Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdomInfo
- Publication number
- DK1256339T3 DK1256339T3 DK01111109T DK01111109T DK1256339T3 DK 1256339 T3 DK1256339 T3 DK 1256339T3 DK 01111109 T DK01111109 T DK 01111109T DK 01111109 T DK01111109 T DK 01111109T DK 1256339 T3 DK1256339 T3 DK 1256339T3
- Authority
- DK
- Denmark
- Prior art keywords
- rotigotine
- parkinson
- therapeutic system
- transdermal therapeutic
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01111109A EP1256339B1 (en) | 2001-05-08 | 2001-05-08 | Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1256339T3 true DK1256339T3 (da) | 2004-02-09 |
Family
ID=8177356
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01111109T DK1256339T3 (da) | 2001-05-08 | 2001-05-08 | Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom |
DK02740569T DK1471892T3 (da) | 2001-05-08 | 2002-05-06 | Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02740569T DK1471892T3 (da) | 2001-05-08 | 2002-05-06 | Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer |
Country Status (15)
Country | Link |
---|---|
EP (3) | EP1344522A1 (da) |
JP (2) | JP5026656B2 (da) |
KR (1) | KR100974974B1 (da) |
CN (2) | CN102172351B (da) |
AT (2) | ATE251901T1 (da) |
CY (1) | CY1109861T1 (da) |
DE (2) | DE60100994T2 (da) |
DK (2) | DK1256339T3 (da) |
ES (2) | ES2204780T3 (da) |
HK (1) | HK1049444B (da) |
HU (1) | HU229350B1 (da) |
PT (2) | PT1256339E (da) |
RU (1) | RU2272625C2 (da) |
WO (1) | WO2002089778A2 (da) |
ZA (1) | ZA200209982B (da) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60100595T2 (de) * | 2001-05-08 | 2004-06-24 | Lts Lohmann Therapie-Systeme Ag | Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson |
DE10220230A1 (de) * | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
DE10361259A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
WO2006039532A2 (en) * | 2004-09-29 | 2006-04-13 | Schwarz Pharma, Inc. | Transdermal therapeutic system for parkinson’s disease |
CN101147739B (zh) | 2007-07-06 | 2010-12-08 | 北京康倍得医药技术开发有限公司 | 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂 |
DE102008060203A1 (de) | 2008-12-07 | 2010-06-10 | Dietrich Wilhelm Schacht | Wirkstoffstabilisierende flächenförmige Vorrichtung |
EP2201941A1 (de) | 2008-12-29 | 2010-06-30 | UCB Pharma GmbH | Pflaster-Herstellungstechnologie |
WO2011048491A2 (en) * | 2009-10-19 | 2011-04-28 | Actavis Group Ptc Ehf | Amorphous rotigotine co-precipitates |
DK2515887T3 (da) | 2009-12-22 | 2018-09-17 | Ucb Biopharma Sprl | Polyvinylpyrrolidon til stabilisering af en faststofdispersion af den ikke-krystallinske form af rotigotin |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
BR112015032929B1 (pt) | 2013-07-03 | 2022-08-23 | Lts Lohmann Therapie-Systeme Ag | Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico |
CA2948221C (en) | 2014-05-20 | 2022-11-22 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
WO2015177209A1 (en) | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
US11633367B2 (en) | 2014-05-20 | 2023-04-25 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
KR102364378B1 (ko) * | 2014-05-21 | 2022-02-16 | 에스케이케미칼 주식회사 | 안정성을 향상시킨 로티고틴 함유 경피흡수제제 |
DE102014114282A1 (de) | 2014-10-01 | 2016-04-07 | Neuraxpharm Arzneimittel Gmbh | Transdermales therapeutisches System mit Rotigotin zur Behandlung von Morbus Parkinson |
WO2018123822A1 (ja) | 2016-12-28 | 2018-07-05 | 久光製薬株式会社 | ブトルファノール含有貼付剤 |
DE102018120506A1 (de) | 2017-10-20 | 2019-04-25 | Amw Gmbh | Stabilisiertes transdermales Darreichungssystem |
EP3854388B1 (de) | 2020-01-24 | 2023-10-04 | Luye Pharma Switzerland AG | Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0751515B2 (ja) * | 1986-09-10 | 1995-06-05 | 明治製菓株式会社 | 経皮吸収製剤 |
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5989586A (en) * | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE19940238A1 (de) * | 1999-08-25 | 2001-03-01 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten |
-
2001
- 2001-05-08 AT AT01111109T patent/ATE251901T1/de active
- 2001-05-08 DK DK01111109T patent/DK1256339T3/da active
- 2001-05-08 PT PT01111109T patent/PT1256339E/pt unknown
- 2001-05-08 ES ES01111109T patent/ES2204780T3/es not_active Expired - Lifetime
- 2001-05-08 EP EP03013353A patent/EP1344522A1/en not_active Withdrawn
- 2001-05-08 DE DE60100994T patent/DE60100994T2/de not_active Expired - Lifetime
- 2001-05-08 EP EP01111109A patent/EP1256339B1/en not_active Expired - Lifetime
-
2002
- 2002-05-06 KR KR1020037000143A patent/KR100974974B1/ko active IP Right Grant
- 2002-05-06 DK DK02740569T patent/DK1471892T3/da active
- 2002-05-06 HU HU0500525A patent/HU229350B1/hu unknown
- 2002-05-06 CN CN2011100516651A patent/CN102172351B/zh not_active Expired - Lifetime
- 2002-05-06 AT AT02740569T patent/ATE444061T1/de active
- 2002-05-06 ES ES02740569T patent/ES2331787T3/es not_active Expired - Lifetime
- 2002-05-06 DE DE60233898T patent/DE60233898D1/de not_active Expired - Lifetime
- 2002-05-06 CN CNA028015401A patent/CN1606435A/zh active Pending
- 2002-05-06 RU RU2003133217/15A patent/RU2272625C2/ru active IP Right Revival
- 2002-05-06 PT PT02740569T patent/PT1471892E/pt unknown
- 2002-05-06 JP JP2002586915A patent/JP5026656B2/ja not_active Expired - Lifetime
- 2002-05-06 WO PCT/EP2002/004976 patent/WO2002089778A2/en active IP Right Grant
- 2002-05-06 EP EP02740569A patent/EP1471892B1/en not_active Revoked
- 2002-12-10 ZA ZA200209982A patent/ZA200209982B/xx unknown
-
2003
- 2003-03-04 HK HK03101599.0A patent/HK1049444B/zh unknown
-
2009
- 2009-11-05 CY CY20091101150T patent/CY1109861T1/el unknown
-
2010
- 2010-01-07 JP JP2010002209A patent/JP2010106037A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20030016373A (ko) | 2003-02-26 |
JP5026656B2 (ja) | 2012-09-12 |
KR100974974B1 (ko) | 2010-08-09 |
CN102172351A (zh) | 2011-09-07 |
WO2002089778A3 (en) | 2004-08-19 |
EP1256339B1 (en) | 2003-10-15 |
HUP0500525A2 (hu) | 2005-09-28 |
EP1471892A2 (en) | 2004-11-03 |
DE60233898D1 (de) | 2009-11-12 |
ATE444061T1 (de) | 2009-10-15 |
EP1344522A1 (en) | 2003-09-17 |
CN1606435A (zh) | 2005-04-13 |
DE60100994D1 (de) | 2003-11-20 |
PT1256339E (pt) | 2004-02-27 |
JP2004536054A (ja) | 2004-12-02 |
DK1471892T3 (da) | 2009-12-07 |
EP1471892B1 (en) | 2009-09-30 |
ES2204780T3 (es) | 2004-05-01 |
PT1471892E (pt) | 2009-12-23 |
HK1049444A1 (en) | 2003-05-16 |
ZA200209982B (en) | 2003-03-24 |
HK1049444B (zh) | 2004-03-19 |
RU2272625C2 (ru) | 2006-03-27 |
WO2002089778A2 (en) | 2002-11-14 |
ES2331787T3 (es) | 2010-01-15 |
RU2003133217A (ru) | 2005-04-20 |
HU229350B1 (en) | 2013-11-28 |
ATE251901T1 (de) | 2003-11-15 |
DE60100994T2 (de) | 2004-07-22 |
CY1109861T1 (el) | 2014-09-10 |
JP2010106037A (ja) | 2010-05-13 |
CN102172351B (zh) | 2013-07-17 |
EP1256339A1 (en) | 2002-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1256339T3 (da) | Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom | |
DK1392256T3 (da) | Forbedret transdermalt behandlingssystem til behandling af Parkinsons sygdom | |
BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
DE60121301D1 (de) | Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen | |
HUP0102728A2 (hu) | Módszerek és transzdermális készítmények fájdalom csillapítására | |
ATE493981T1 (de) | Einmal tägliche dosierformen von trospium | |
DE50005529D1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
PT1383752E (pt) | 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos | |
DE60211139D1 (de) | Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp | |
GEP201606538B (en) | Preoperative treatment of post operative pain | |
SE0102887D0 (sv) | New formulation | |
HK1065305A1 (en) | Substituted 4-aminocyclohexanol derivatives | |
TR200301916T4 (tr) | Rotigotinin yüksek plazma seviyelerini kapsayan parkinson hastalığına yönelik transdermal terapötik sistem. |